Moderna Omicron-Targeting Booster Candidates Demonstrate Superiority Over its Spikevax Booster
November 14th 2022Safety profile in this study showed the frequency of adverse reactions with these boosters were similar or lower than that of either a second or third dose of the original vaccine.
Read More
COVID-19 Vaccine Boosters: Roadblocks, the Future, and Communicating the Benefits to Patients
October 31st 2022“In the long run, what we will have is a virus that will become endemic in our population," said Donald J. Alcendor, MD. "The idea of thinking we can chase variants with boosters is a failed effort. We must realize that.”
Read More
Overview of SARS-CoV-2 Virus and Subvariants
Jacinda Abdul-Mutakabbir, PharmD, discusses the difference between the original SARS-CoV-2 strain and subvariant strains.
Read More
Moderna’s Bivalent COVID-19 Booster Elicits Superior Antibody Responses
October 14th 2022Moderna’s new bivalent COVID-19 booster, which includes 25 micrograms each of messenger RNAs from the Wuhan-Hu-1 and Omicron B.1.1.529 variants of SARS-CoV-2, elicited antibody responses that were superior to those elicited by the original vaccine.
Read More